r/ResearchCompounds • u/Sea-Performer-71 • 21h ago
Discussion The GLP-1 eating disorder overlap is now showing up in the data, not just anecdotes
WSJ ran a piece on people who used GLP-1s for weight loss and later ended up in treatment for anorexia:
https://www.wsj.com/health/wellness/glp1-anorexia-wegovy-mounjaro-1bf4035c
Worth reading alongside the primary literature from the past few months, because the reporting is no longer just anecdotal.
A JAMA Psychiatry survey published this summer (Levinson and colleagues) recruited 436 people with diagnosed eating disorders in 2025 and asked about GLP-1 use. Just over 32% reported having ever used one, and 22% reported current use. Broken out by diagnosis, a little over 50% of participants with binge eating disorder reported use, about 42% of those with atypical anorexia nervosa, roughly 30% of those with ARFID, over 25% of those with bulimia, and about 11% of those with anorexia nervosa. Roughly 10% obtained them through online providers prescribing compounded formulations. Over 10% reported misuse, defined as taking more or less than prescribed, using longer than prescribed, tampering with injection equipment, or sharing without a prescription.
The authors described the weight loss market as a rapidly evolving risk environment for this population.
Summary of the findings:
https://www.medscape.com/viewarticle/many-eating-disorder-patients-using-glp-1s-2026a1000lym
In April, NEJM published a perspective by Amanda Banks raising the same concern from the prescribing side. She noted the share of GLP-1 prescriptions written for people who were not diabetic, obese, or overweight rose from 4.5% in 2018 to 17% in 2023, and argued for consensus recommendations to protect people with existing or emerging eating disorders. A 2023 FDA analysis found misuse reports for semaglutide were roughly four times higher than for other GLP-1 drugs.
NEJM perspective:
https://www.nejm.org/doi/full/10.1056/NEJMp2600300
Clinician-side reporting describes the same pattern from treatment centers, including patients presenting at very low BMI while still dosing.
NPR, February 2026: https://www.npr.org/2026/02/04/nx-s1-5677633/glp-1-obesity-wegovy-zepbound-eating-disorders-anorexia-bulimia
Washington Post, May 2026: https://www.washingtonpost.com/health/2026/05/23/weight-loss-drugs-pose-dangers-people-with-eating-disorders/
MindSite News, May 2026: https://mindsitenews.org/2026/05/29/glp-1-access-a-problem-for-people-with-eating-disorders/
The mechanism cuts both ways, which is part of why this is hard to legislate around. A 2025 systematic review and meta-analysis found GLP-1 agonists reduced Binge Eating Scale scores by about 8 points, though the pooled sample was only 182 participants across five studies and heterogeneity was high. WSJ also covered that side on July 13 in a piece on clinicians treating certain eating disorders with these drugs. The same appetite and reward suppression that helps in binge-type presentations appears to reinforce restriction in people with a restrictive history. Same drug class, opposite clinical valence depending on phenotype.
Meta-analysis: https://link.springer.com/article/10.1007/s40519-025-01720-9
Penn Medicine's eating disorder program has said outright that no protocol exists to screen for eating disorders before prescribing GLP-1 receptor agonists. That gap widens with telehealth and disappears entirely outside a clinical relationship.
Penn Medicine:
ANAD clinical guidance:
https://anad.org/learning-library/glp-1-medications-eating-disorders/
More stories at r/PeptideTides
